IGF1 Protein (AA 49-118)

N° du produit ABIN2667446

Cette protéine Recombinant IGF1 est exprimée dans Escherichia coli (E. coli).

Aperçu rapide pour IGF1 Protein (AA 49-118) (ABIN2667446)

Antigène: IGF1 (Insulin-Like Growth Factor 1 (IGF1))

Type de proteíne: Recombinant

Activité biologique: Active

Origine: Humain

Source: Escherichia coli (E. coli)

Application: Flow Cytometry (FACS)

Pureté: >98 % , as determined by Coomassie stained SDS-PAGE and HPLC analysis.

Détail du produit

Attributs du protein: AA 49-118

niveau d'endotoxine:

Less than 0.1 ng per μg of protein.

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Commentaires:

Biological activity: The ED50 was determined by a cell proliferation assay using FDC-P1 cells is ≤ 2.0 ng/ml, corresponding to a specific activity of ≥ 5 x 105 units/mg.

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: For maximum results, quick spin vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/mL. Do not vortex. It is recommended to further dilute in a buffer, such as 5 % Trehalose, and store working aliquots at -20 °C to -80 °C.

Buffer: Lyophilized, carrier-free.

Conseil sur la manipulation: Avoid repeated freeze/thaw cycles.

Stock: -20 °C

Stockage commentaire: Unopened vial can be stored at -20°C or -70°C.

Détail du antigène

Antigène: IGF1 (Insulin-Like Growth Factor 1 (IGF1))

Autre désignation: IGF-I

Sujet: IGF-I (insulin-like growth factor 1), initially described in 1957, is a hormone that is important in childhood growth and also has anabolic effects in adults. It is a member of the IGF family that is comprised of three members: IGF-I, IGF-II, and insulin. IGF-I and IGF-II share approximately 50 % similarity with insulin at the amino acid level. Human IGF-I is synthesized as a 191 amino acid prepro-IGF-I, pro-IGF-I is processed to the mature, active protein, and this procedure requires glucose regulating protein 94 (GRP94) that possesses chaperone activity towards IGF-I. Deletion of muscle GRP94 impairs muscle and body growth by inhibiting local production of IGF proteins. Seven IGF binding proteins have been described (IGFBP-1 to -7). IGFBPs extend the half life and regulate the availability of IGF-I and IGF-II. It has been described that IGFBP3 is the main circulating binding protein for IGFs, in serum, approximately 75 % of circulating IGF-I and IGF-II bind to IGFBP3 and the co-carrier acid labile subunit (ALS). IGF-I binds to three receptors, and the binding to IGFIR promotes cell proliferation, survival, differentiation, and migration. IGF-I deficiency is associated to growth hormone insensitivity syndrome (GHIS) also called Laron syndrome, liver cirrhosis, age-related cardiovascular and neurological diseases, and intrauterine growth restriction.

Poids moléculaire: The 70 amino acid recombinant protein has a predicted molecular mass of approximately 7.6 kDa. The predicted N-terminal amino acid is Gly.

Pathways: Signalisation RTK, Intracellular Steroid Hormone Receptor Signaling Pathway, Peptide Hormone Metabolism, Hormone Activity, Regulation of Intracellular Steroid Hormone Receptor Signaling, Regulation of Hormone Metabolic Process, Regulation of Hormone Biosynthetic Process, Stem Cell Maintenance, Glycosaminoglycan Metabolic Process, Regulation of Carbohydrate Metabolic Process, Autophagy, Smooth Muscle Cell Migration, Activated T Cell Proliferation, Positive Regulation of fat Cell Differentiation